The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature

Wien Med Wochenschr. 2011 Apr;161(7-8):192-203. doi: 10.1007/s10354-010-0853-7. Epub 2011 Jan 25.

Abstract

Introduction: Arginine-vasopressin (AVP) and terlipressin (TP) are used as rescue drugs for states of shock and cardio-circulatory failure.

Methods: Review to assess AVP/TP as a rescue therapy in children with catecholamine-resistant shock or cardio-circulatory arrest.

Results: A total of 31 reports were included (428 patients); sixteen articles were case series, 10 case reports, 3 clinical evaluation studies, one study was a non-blind RCT while one study was a multicentre double-blind RCT. The most common indication for either drug was catecholamine-refractory septic shock (12 reports). Commonly reported responses following AVP/TP administration were a rapid increase in blood pressure, an increase in urine output, and a decrease in serum lactate. In most reports, AVP and TP led to the reduction of catecholamines. The cumulative mortality rate remained high (188/428; 43.9%) despite the use of AVP/TP.

Conclusions: No firm recommendations on the use of AVP/TP in children with severe forms of cardio-circulatory failure can be issued.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Arginine Vasopressin / adverse effects
  • Arginine Vasopressin / therapeutic use*
  • Cardiac Output, Low / drug therapy
  • Cardiac Output, Low / mortality
  • Cardiopulmonary Resuscitation
  • Catecholamines / administration & dosage
  • Catecholamines / blood
  • Catecholamines / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Resistance
  • Female
  • Heart Arrest / drug therapy*
  • Heart Arrest / mortality
  • Hemodynamics / drug effects
  • Hospital Mortality
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature, Diseases / drug therapy
  • Infant, Premature, Diseases / mortality
  • Lypressin / adverse effects
  • Lypressin / analogs & derivatives*
  • Lypressin / therapeutic use
  • Male
  • Randomized Controlled Trials as Topic
  • Shock, Cardiogenic / drug therapy*
  • Shock, Cardiogenic / mortality
  • Shock, Septic / drug therapy*
  • Shock, Septic / mortality
  • Survival Rate
  • Terlipressin
  • Young Adult

Substances

  • Catecholamines
  • Arginine Vasopressin
  • Lypressin
  • Terlipressin